MANNKIND CORP — Director's Dealing 2025

May 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MANNKIND CORP (MNKD)
CIK: 0000899460
Period of Report: 2025-05-14

Reporting Person: Marasco Dominic (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-05-14	Common Stock, $0.01 Par Value	A	59500	—	Acquired	311500	Direct
2025-05-14	Common Stock, $0.01 Par Value	A	21929	$4.56	Acquired	333429	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-05-14	Performance Restricted Stock Unit	$	A	72500	Acquired		Common Stock, $0.01 Par Value (72500)	Direct

Footnotes

F1: Acquired pursuant to a Restricted Stock Unit Award: 25% vest on July 15, 2026 and each yearly anniversary thereof until fully vested. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F2: The securities were purchased through the Issuer's Market Price Stock Purchase Plan effective May 13, 2023. The purchase was approved by the Company's Board of Directors on May 14, 2025.

F3: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

F4: The performance-based restricted stock unit will vest on July 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2025 until June 30, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.